A systematic review of proteomic biomarkers associated with risk stratification in pediatric acute lymphoblastic leukemia by Dehghan-Nayeri, Nasrin et al.







A systematic review of proteomic biomarkers associated with risk 













 1Pediatric Congenital Hematologic Disorders Research Center, School of Medicine, Shahid Beheshti University of Medical 
Sciences, Tehran, Iran 
2Department of Hematology and Blood Bank, School of Allied Medical Sciences, Shahid Beheshti University of Medical 
Sciences, Tehran, Iran 
 




     Risk-based therapy protocols have dramatically improved survival rates in more than 80% of 
childhood acute lymphoblastic leukemia (chALL). Prognostic biomarkers could be valuable for predicting 
the relapsed ALL patients and may therefore contribute to improving ALL outcome. Presently, there are 
little data on the role of prognostic biomarkers in the risk stratification of ALL. The aim of the present 
systematic review is to survey the identified prognostic biomarkers of chALL. In this study, protein-
protein interaction of identified biomarkers was evaluated to reveal the biological pathways related to 
high risk chALL. To pursue this goal, firstly all relevant studies were collected through the PubMed and 
Google Scholar databases with no restrictions. Then, the biomarkers of high risk patients were recorded 
and finally protein-protein interaction of biomarkers was analyzed through using the STRING database. 
After screening 82 abstracts, three studies were included with 36 high risk and 33 low risk B-ALL 
participants. Totally, 142 biomarkers were investigated in this study. Protein interaction network analysis 
of biomarkers revealed two main pathways, namely ribosome and spliceosome. Dysregulation of two key 
pathways, ribosome and spliceosome can be associated with the high risk phenotype of childhood acute 
lymphoblastic leukemia. 
 




     Despite improvements in risk-based therapy 
regimens, nearly 20-30% of the children with 
ALL suffer from a relapse [1]. Inappropriate 
classification of risk groups leads to poor 
outcome in patients. Indeed, the main reason for 
the complexity of precise risk stratification in 
chALL is due widely to its clinical heterogeneity 
[2]. Currently, significant risk stratification 
factors in chALL comprise age, white cell count, 
genetic abnormalities, prednisolone response, 
and determination MRD (minimal residual 
disease) by flow cytometry or PCR [3]. In 
addition to these risk factors, predictive markers 
can provide clinically important prognostic 
information for optimal utilization of 
chemotherapy strategies [4]. Additionally, risk-
stratification biomarkers as a complementary 
approach can help avoid inessential intensive 
chemotherapy in low-risk patients and selection 
of optimal chemotherapy regimens in high risk 
individuals [5]. To the best of our knowledge, 
there has been no reported systematic evaluation 
of the prognostic biomarkers in chALL. 
Accordingly, a systematic review of available 
manuscripts was performed to investigate the 





prognostic biomarkers and also pathways involved in these proteins. 
MATERIAL AND METHOD  
Studies eligible for review 
     PubMed and Google Scholar databases were 
searched using the terms ‘acute lymphoblastic 
leukemia’, ‘proteomic’, as well as one of the 
following title/abstract phrases ‘childhood’ or 
‘pediatric’, ‘proteomics’, ‘biomarker’, 
‘prognosis’, and ‘risk factor’ with no language 
restriction. Animal studies, adult studies, those 
which applied proteomics to different ALL 
groups (e.g. with T-ALL, AML, …) or which 
presented their results as peaks and not as named 
proteins were excluded. Studies were deemed 
eligible if a) patient population was B-ALL 
subset of chALL; b) patient samples (BM or PB) 
were collected at diagnosis; c) patients divided 
into two groups of high and low risk; d) the 
studies were investigated through using 
proteomic methods.  
Data Abstraction 
     Titles and abstracts of collected articles were 
screened and the full text of selected literatures 
was evaluated. Additionally, the handsearching 
of references from all the researches was 
planned to identify any other potentially relevant 
studies. The search ended in August 2016. The 
search findings were independently assessed by 
2 of the authors (ND and AG). This process has 
been summarized in Figure 1. 
 
 
Figure 1. A flow chart of summarizing the selection process of the literatures 
 
The main characteristics of the articles 
     The selected articles were screened and 
specific characteristics of the studies were 
recorded. These characteristics include: type of 
sample collected at diagnosis (e.g. bone marrow 
(BM) or peripheral blood (PB)), number of 
participants in high risk or low risk groups, the 
age range of patients and type of proteomic 
technique. Finally, a list of differentially 
expressed proteins in high risk patients versus 




To minimize selection bias, screening of the 
studies  
was independently performed by 2 of the authors 
(KG and PE). 
Construction of the protein-protein interaction 
network 
     Protein-protein interaction (PPI) network was 
constructed by STRING v10 database 
(http://string-db.org) with highest confidence 
(0.900). 
 




Table 1. Three publications containing potentially prognostic chALL biomarker data that were analyzed.BM, bone marrow; PB, 
peripheral blood; HR, high risk; LR, low risk; 2DE, two-dimensional gel electrophoresis; LC-ESI-MS/MS,  liquid 
chromatography-electrospray ionization-tandem mass spectrometry; MALDI-TOF MS, matrix-assisted Laser 
Desorption/Ionization Mass Spectrometry; SELDI-TOF MS, Surface-enhanced laser desorption ionization time-of-flight mass 




     Initial database searches provided 82 eligible 
articles within the literature for inclusion. After 
removing 10 duplicates, 72 exclusive abstracts 
were screened among which, 66 were excluded, 
mostly due to a lack of inclusion criteria, and 
finally the full text of 6 articles were evaluated. 
Three articles were excluded after reviewing the 
full text, essentially due to the investigation of 
ALL diagnostic biomarkers and not prognostic. 
Totally, three articles including 36 high risk and  
 
 
33 low risk B-ALL participants provided the 
suitability criteria and were included in this 
study. 
Protein-protein interaction network 
     Investigation of three studies provided a total 
of 142 biomarkers in ALL high risk patients. 
Analyzing protein-protein interaction of 142 
biomarkers using STRING database revealed 
two main pathways, namely ribosome and 











Proteomic biomarkers discovered 








0.5-11 LC-ESI MS/MS 
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Figure 2. Protein-protein interaction network of biomarkers in high risk ALL patients using the STRING database (A) Proteins 
involved in spliceosome pathway (B) Proteins involved in ribosome pathway 
 
DISCUSSION  
     The assessment of minimal residual disease 
(MRD) in acute lymphoblastic leukemia (ALL) 
is presently considered as a potentially valuable 
tool to evaluate the relapse rate of therapy [6]. 
Currently, multi-parameter flow cytometry and 
polymerase chain reaction are useful methods 
for identifying the MRD in ALL patients [7]. 
Prognostic markers of relapsed ALL are the new 
approach to the detection of MRD in high risk 
patients. The proteomic analysis can be used as 
one of the best tools to detect specific 
biomarkers in order to discriminate high risk and 
low risk patients with various degrees of 
remission [8]. Hence, in this systematic review, 
the identified biomarkers of high risk ALL 
patients were assessed through using the 
proteomic techniques.  To better understand the 
signaling pathways involved in high risk ALL, 
protein-protein interaction of identified 
biomarkers were evaluated using the STRING 
database. STRING data revealed that a large 
number of proteins were localized in two 
pathways, namely ribosome and spliceosome.  
Ribosome pathway plays a pivotal role in 
forming the most of cellular proteins and is 
essential for cell growth [9]. The mutation in 
ribosomal genes was recognized in the genome 
of hematologic malignancies, including T-cell 
acute lymphoblastic leukemia and chronic 
lymphocytic leukemia [10,11]. Additionally, 
ribosomal proteins as the poor prognostic factors 
are detected in various kinds of cancers such as 
colorectal, glioblastoma, pancreatic, ovarian and 
gastric cancers [12-16].  
The other recognized pathway in this study was 
spliceosome pathway. Dysfunction of the 
splicing machinery is closely related to various 
human cancers, including acute myeloid 
leukemia (AML) [17]. Evaluating the expression 
level of the alternative splicing isoforms in 
tumors can distinguish tumor cells from the 
normal ones; moreover, it may predict patient 
survival [18]. Additionally, it has been 
demonstrated  that splicing factors contribute to 
resistance of cancer cells to chemotherapy plus 
the fact that splicing factor inhibitors may be 
considered as target therapy in various cancers 
such as chronic lymphocytic leukemia (CLL) 
[19,20]. On the other hand, the mutation in 
splicing factors has been reported in T-cell acute 
lymphoblastic leukemia [21].    
All in all, in this study, the potential prognostic 
role of ribosomal proteins and splicing factors in 
high risk group of B-ALL patients was 
indicated. Investigating the expression level of 




these proteins in the clinical setting is needed to 
confirm this hypothesis.  
 
CONCLUSION 
     To sum up, results of the present study 
revealed that the dysregulation of two key 
pathways, ribosome and spliceosome can be 
associated with the high risk phenotype of 
childhood acute lymphoblastic leukemia. These 
findings suggest that mutations in the ribosome 
and spliceosome pathways may lead to 
modifying the genetic program of the cancer 
cells to maintain survival. Investigation of 
proteins involved in these two pathways could 
provide prognostic, diagnostic and therapeutic 
tools for the monitoring and treatment of 
patients with ALL. 
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